Page last updated: 2024-12-08

8-chloroadenosine-3',5'-cyclic monophosphorothioate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

8-chloroadenosine-3',5'-cyclic monophosphorothioate: inhibits growth of human cancer cells; the Rp-isomer is more potent than the Sp-isomer; RN given refers to the (S)- isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID133987
MeSH IDM0200298

Synonyms (15)

Synonym
quinato(chda)pt
142754-28-7
(1,2-cyclohexanediamine-n,n')(1,3,4,5-tetrahydroxycyclohexanecarboxylato(2-))platinum (sp-4-3-1(3r-(1alpha,3alpha,4alpha,5beta)),3(1r-trans))-
rp-8-cl-camps
quinato(cyclohexanediamine)platinum(ii)
platinum, (1,2-cyclohexanediamine-n,n')(1,3,4,5-tetrahydroxycyclohexanecarboxylato(2-))-, (sp-4-3-1(3r-(1alpha,3alpha,4alpha,5beta)),3(1r-trans))-
sp-8-cl-camps
adenosine, 8-chloro-, cyclic 3',5'-(hydrogen phosphorothioate), (s)-
8-chloro-camps
142928-30-1
8-chloroadenosine-3',5'-cyclic monophosphorothioate
(sp-4-3-1(3r-(1alpha,3alpha,4alpha,5beta)),3(1r-trans))-(1,2-cyclohexanediamine-n,n')(1,3,4,5-tetrahydroxycyclohexanecarboxylato(2-))platinum
DTXSID80931626
platinum(2+) 3,4,5-trihydroxy-1-oxidocyclohexane-1-carboxylate--cyclohexane-1,2-diamine (1/1/1)
cyclohexane-1,2-diamine;platinum(2+);3,4,5-trihydroxy-1-oxidocyclohexane-1-carboxylate

Research Excerpts

Compound-Compound Interactions

ExcerptReferenceRelevance
" In other words, PKA inhibitors by themselves do not affect orientation selectivity, nor does monocular deprivation by itself, but monocular deprivation in combination with a PKA inhibitor does affect orientation selectivity."( Orientation selectivity is reduced by monocular deprivation in combination with PKA inhibitors.
Beaver, CJ; Daw, NW; Fischer, QS; Ji, Q, 2002
)
0.31
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (17)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's6 (35.29)18.2507
2000's9 (52.94)29.6817
2010's2 (11.76)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.49

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.49 (24.57)
Research Supply Index2.89 (2.92)
Research Growth Index4.38 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.49)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other17 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]